ReviewFrontiers in epidemiology2026
Global prevalence and predictors of depression and anxiety in patients with liver cirrhosis: a systematic review and meta-analysis.
Review in Frontiers in epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver cirrhosis is a complex disorder that affects nearly 122 million patients worldwide. This study synthesizes global prevalence estimates of depression and anxiety among patients with cirrhosis, together with associated risk factors and geographic distribution. Method: An electronic search was conducted on Medline, Embase, Cochrane Central and Web of Science databases. Results were then filtered according to the inclusion criteria over two stagesData from eligible studies were extracted into a standardized spreadsheet, which was then subjected to analysis and evidence synthesis. Results: Our search yielded 23 articles from countries all over the world describing 979,113 patients.The pooled prevalence was 0.37 [95% C.I. 0.29-0.46, Conclusion: Depression and anxiety substantially impair quality of life in patients with cirrhosis, but their diagnosis remains limited and under-investigated. Standardizing depression and anxiety screening for cirrhosis patients can improve their outcomes and quality of life significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.